Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation

• Published in: Bone marrow transplantation (Basingstoke) Vol. 36; no. 12; pp. 1077 - 1082
• Main Authors: KUITTINEN, T, HUSSO-SAASTAMOINEN, M, SIPOLA, P, VUOLTEENAHO, O, ALA-KOPSALA, M, NOUSIAINEN, T, JANTUNEN, E, HARTIKAINEN, J
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.12.2005
• Subjects: Adult; Aged; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Anthracycline; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Autografts; Biological and medical sciences; Bone marrow; Bone marrow, stem cells transplantation. Graft versus host reaction; Cancer; Cardiotoxicity; Cardiovascular System - pathology; Care and treatment; Carmustine - therapeutic use; Chemotherapy; Cyclophosphamide - therapeutic use; Cytarabine - therapeutic use; Drug toxicity and drugs side effects treatment; Etoposide - therapeutic use; Female; Health aspects; Heart; Heart - drug effects; Humans; Lymphoma; Lymphoma, Non-Hodgkin - complications; Lymphoma, Non-Hodgkin - therapy; Magnetic Resonance Imaging; Male; Medical sciences; Methods; Middle Aged; Natriuretic Peptides - blood; Non-Hodgkin's lymphoma; Non-Hodgkin's lymphomas; Peptides; Peptides - chemistry; Pharmacology. Drug treatments; Plasma levels; Prognosis; Prospective Studies; Stem cell transplantation; Stem Cell Transplantation - methods; Stem cells; Time Factors; Toxicity; Toxicity: cardiovascular system; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation; Transplantation, Autologous; Ventricle; Ventricular Dysfunction, Left - diagnosis; Ventricular Function, Left; Finland; Antineoplastic agent; magnetic resonance imaging; Toxicity; Stem cell; Hematopoietic cell; Cardiovascular disease; Atrial natriuretic peptide; natriuretic peptides; Autograft; Natriuretic hormone; Isomerases; Cancerology; Cytarabine; non-Hodgkin's lymphoma; Heart disease; Lymphoproliferative syndrome; Graft; Complication; Antimitotic; High dose; Human; Heart failure; DNA topoisomerase (ATP-hydrolysing); Drug combination; Hematology; Enzyme; Acute; Carmustine; Enzyme inhibitor; Etoposide; Malignant hemopathy; Non Hodgkin lymphoma; Nuclear magnetic resonance imaging; Podophyllotoxine derivatives; high-dose therapy; Alkylating agent; Oxazaphosphinane derivatives; Chemotherapy; Cyclophosphamide; cardiotoxicity; Treatment; Nitrogen mustard; Medical imagery; Therapeutic protocol

Cardiotoxicity is potentially the most threatening nonhaematological side effect of high-dose CY. We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adult non-Hodgkin's lymphoma (NHL) patients receiving CY 1500 mg/m2/day as a part of BEAC high-dose therapy (HDT). Ma...